$CAMP News

Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10

CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease

Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8

CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference

Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6

Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript

CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002

Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day - Slideshow

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

CAMP4 Therapeutics Receives MHRA Authorization To Include UK Sites In Global Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic Candidate For Patients With SYNGAP1-Related Disorder

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

CAMP4 Therapeutics To Host Virtual Analyst Day To Demonstrate CMP-002 Data To Treat SYNGAP1-Related Disorder

CAMP4 to Participate in Upcoming Investor Conferences

Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

Camp4 Therapeutics Q2 EPS $(0.58) Misses $(0.21) Estimate, Sales $1.779M Miss $1.897M Estimate

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

CAMP4 Moves Into Human Trials -- The Upside Is Underpriced

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder